Table 1 Baseline characteristics
m-FOLFOXIRI + cetuximab (n = 159) | m-FOLFOXIRI + bevacizumab (n = 162) | |
|---|---|---|
Sex, n (%) | ||
Male/Female | 101 (63.5)/58 (36.5) | 106 (65.4)/56 (34.6) |
Age (years), median (range) | 65 (26–83) | 65 (29–85) |
ECOG performance status, n (%) | ||
0/1 | 146 (91.8)/13 (8.2) | 146 (90.1)/16 (9.9) |
Adjuvant chemotherapy, n (%) | ||
None/With oxaliplatin/Without oxaliplatin | 148 (93.1)/7 (4.4)/4 (2.5) | 152 (93.8)/6 (3.7)/4 (2.5) |
Primary tumor site, n (%) | ||
Colon/Rectum | 91 (57.2)/68 (42.8) | 93 (57.4)/69 (42.6) |
Site of primary tumor, n (%) | ||
Right/Left | 27 (17.0)/132 (83.0) | 25 (15.4)/137 (84.6) |
Resected primary tumor, n (%) | ||
Yes/No | 83 (52.2)/76 (47.8) | 86 (53.1)/76 (46.9) |
Time to metastases, n (%) | ||
Synchronous/Metachronous | 136 (85.5)/23 (14.5) | 136 (84.0)/26 (16.0) |
Number of metastatic sites, n (%) | ||
0-1/ > 1 | 55 (34.6)/104 (65.4) | 80 (49.4)/82 (50.6) |
Liver-only disease, n (%) | ||
Yes/No | 39 (24.5)/120 (75.5) | 50 (30.9)/112 (69.1) |
Metastatic sites, n (%) | ||
Liver | 119 (74.8) | 116 (71.6) |
Lung | 44 (27.7) | 37 (22.8) |
Lymph node | 98 (61.6) | 81 (50.0) |
Peritoneum | 31 (19.5) | 25 (15.4) |
Bone | 3 (1.9) | 4 (2.5) |
BRAF V600E status | ||
wild / mutant/unknown | 72/8/79 | 81/6/75 |
UGT1A1 (*6, *28), n (%) | ||
Wild/hetero/homo & double hetero/unknown | 65 (40.9)/59 (37.1)/9 (5.7)/26 (16.4) | 69 (42.6)/46 (28.4)/22 (13.6)/25 (15.4) |
